Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10500914" target="_blank" >RIV/00216208:11110/25:10500914 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/25:10500914 RIV/00064203:_____/25:10500914
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=jTTYD9hIwR" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=jTTYD9hIwR</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-025-02732-1" target="_blank" >10.1038/s41375-025-02732-1</a>

Result language
angličtina
Original language name
Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia
Original language description
Asciminib, an allosteric inhibitor specifically targeting the myristoyl pocket of BCR::ABL1, has expanded therapeutic options for heavily pretreated patients with chronic myeloid leukemia (CML), and for those with the BCR::ABL1 T315I mutation. Several clinical studies evaluating asciminib in frontline CML therapy are currently ongoing (e.g., ASCI4FIRST, ASCI4START, ASCEND), with promising preliminary results indicating superior efficacy, improved tolerability, and a lower rate of treatment discontinuation due to toxicity compared to ATP-competitive inhibitorsHowever, clinical trials of asciminib in both advanced-line and first-line CML treatment also report the emergence of resistance, often due to acquired or persisting mutations in BCR::ABL1. The full spectrum of these mutations remains unidentified, underscoring the need for further investigation and the exploration of backup therapeutic strategies, including combination therapies.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/NW24-03-00056" target="_blank" >NW24-03-00056: Molecular base for therapy with BH3 mimetics to overcome refractory/relapsed Ph+ leukemias</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)